Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > REGULATORY
REGULATORY
- Deduction Formula for IP Box Tax Relief Now Clear as Preparations Move Ahead
February 22, 2024
- LDP Panel OKs Bill to Amend Regenerative Medicine Safety Act, but Lawmakers Fret Lack of Ban on “Designer Babies”
February 22, 2024
- Japan to Revisit Vaccine Lot Release Process to Eradicate Double Testing
February 22, 2024
- New Doctor Payment Disclosure Rule to Apply to Foreign Firms with Japan Subsidiaries
February 21, 2024
- Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
- AMED Selects 6 VCs for Biotech Startup Funding Project
February 21, 2024
- MEXT to Ask University Hospitals to Create Reform Plan by June
February 21, 2024
- Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
- MHLW Announces Revised Rule for Info Disclosure of Physician Payments
February 19, 2024
- 12 VEGF Inhibitors Ordered to Add Artery Dissection Risk to ADR List
February 19, 2024
- Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29
February 16, 2024
- Japan Approves 1st Generics for 4 APIs towards June Listing, All See AGs
February 16, 2024
- Japan to Ponder New COVID Vaccine Composition from Spring
February 15, 2024
- Japan to Announce New Drug Prices on March 5
February 15, 2024
- AMED Chief Eyes 20-30% Team Expansion by FY2029
February 14, 2024
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
- MHLW to Review Pig Kidney Transplant Plan Including Ethical Issues: Minister
February 14, 2024
- Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
- Active Pharma Slapped with Biz Improvement Order for Illicit API Production
February 13, 2024
- MHLW Panel to Draw Up Report by Year-End towards Amendment of PMD Act
February 13, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…